Marcel R.M. van den Brink
Marcel R.M. van den Brink[edit]
Marcel R.M. van den Brink is a prominent physician-scientist known for his contributions to the field of hematology and oncology. He is particularly recognized for his research on hematopoietic stem cell transplantation and graft-versus-host disease (GVHD).
Education and Career[edit]
Dr. van den Brink received his medical degree from the University of Leiden in the Netherlands. He completed his residency in internal medicine at the Leiden University Medical Center. Following this, he pursued a fellowship in hematology and oncology at the National Institutes of Health (NIH) in the United States.
Currently, Dr. van den Brink is the Head of the Division of Hematologic Malignancies at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City. He is also a Professor of Medicine at Weill Cornell Medical College.
Research Contributions[edit]
Dr. van den Brink's research focuses on improving the outcomes of hematopoietic stem cell transplantation. His work has significantly advanced the understanding of graft-versus-host disease, a common complication of bone marrow transplantation.
He has published extensively on the role of the immune system in cancer and transplantation. His studies have explored the mechanisms of immune reconstitution and the development of novel strategies to prevent and treat GVHD.
Awards and Honors[edit]
Dr. van den Brink has received numerous awards for his contributions to medical research. He is a recipient of the American Society of Hematology's Scholar Award and has been recognized by the American Association for Cancer Research.
External Links[edit]
- [Memorial Sloan Kettering Cancer Center Profile](https://www.mskcc.org/research-areas/labs/marcel-van-den-brink)
- [PubMed Publications](https://pubmed.ncbi.nlm.nih.gov/?term=Marcel+R.M.+van+den+Brink)
References[edit]
<references />
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian